EGFR tyrosine kinase inhibitor erlotinib exhibits antimetastatic activity against inflammatory breast cancer

被引：0

作者：

Ueno, Naoto ^{[1
]}

LaFortune, Tiffany ^{[1
]}

Hortobagyi, Gabriel ^{[1
]}

Lucci, Anthony ^{[1
]}

Singh, Balraj ^{[1
]}

Krishnamurthy, Savitri ^{[1
]}

Esteva, Francisco ^{[1
]}

Hung, Mien-Chie ^{[1
]}

Zhang, Dongwei ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

CANCER RESEARCH | 2009年 / 69卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1767

引用

页数：1

共 50 条

[1] Reishi sensitizes EGFR-overexpressing inflammatory breast cancer cells to the tyrosine kinase inhibitor erlotinib
Suarez-Arroyo, I. J.
Maldonado-Martinez, G.
Cubano, L. A.
Martinez-Montemayor, M.
MOLECULAR BIOLOGY OF THE CELL, 2014, 25
[2] Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer Progression
Suarez-Arroyo, Ivette J.
Rios-Fuller, Tiffany J.
Feliz-Mosquea, Yismeilin R.
Lacourt-Ventura, Mercedes
Leal-Alviarez, Daniel J.
Maldonado-Martinez, Geronimo
Cubano, Luis A.
Martinez-Montemayor, Michelle M.
JOURNAL OF CANCER, 2016, 7 (05): : 500 - 511
[3] Suppression of mesenchymal phenotype in inflammatory breast cancer by EGFR tyrosine kinase inhibitor erlotinib: a novel approach to suppressing metastasis
Ueno, N. T.
Kazansky, A.
LaFortune, T. A.
Lucci, A.
Krishnamurthy, S.
Hung, M. C.
Hortobagyi, G. N.
Woodward, W.
Reuben, J. M.
Robertson, F.
Cristofanilli, M.
Zhang, D.
CANCER RESEARCH, 2009, 69 (02) : 168S - 169S
[4] Effects of EGFR Tyrosine Kinase Inhibitor Erlotinib in Prostate Cancer Cells In Vitro
Festuccia, Claudio
Gravina, Giovanni Luca
Biordi, Leda
D'Ascenzo, Sandra
Dolo, Vincenza
Ficorella, Corrado
Ricevuto, Enrico
Tombolini, Vincenzo
PROSTATE, 2009, 69 (14): : 1529 - 1537
[5] Cancer combination therapy of the sesquiterpenoid artesunate and the selective EGFR-tyrosine kinase inhibitor erlotinib
Efferth, Thomas
PHYTOMEDICINE, 2017, 37 : 58 - 61
[6] Leukocytociastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib
Boeck, S.
Wollenberg, A.
Heinemann, V.
ANNALS OF ONCOLOGY, 2007, 18 (09) : 1582 - 1583
[7] Discovery of an EGFR tyrosine kinase inhibitor from Ilex latifolia in breast cancer therapy
Wang, Cunqin
Wang, Rongbin
Chen, Ying
Wang, Lei
Zhou, Shoubiao
Wang, Hongting
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (11) : 1282 - 1290
[8] Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib
Tartarone, Alfredo
Lazzari, Chiara
Lerose, Rosa
Conteduca, Vincenza
Improta, Giuseppina
Zupa, Angela
Bulotta, Alessandra
Aieta, Michele
Gregorc, Vanesa
LUNG CANCER, 2013, 81 (03) : 328 - 336
[9] Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity
Troiani, Teresa
Cascone, Tina
Heymach, John
Ciardiello, Fortunato
CURRENT CANCER THERAPY REVIEWS, 2007, 3 (04) : 236 - 241
[10] An evaluation of the possible interaction of gastric acid suppressive medication and the EGFR tyrosine kinase inhibitor erlotinib
Hilton, J. F.
Seymour, L.
Le Maitre, A.
Tu, D.
Shepherd, F. A.
Bradbury, P. A.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

← 1 2 3 4 5 →